ERBB2 and breast carcinoma: Germline mutation profile was assessed genome-widely in blood using Illumina HiSeq 2000[59], and whole genome sequencing (WGS) and whole exome sequencing (WES) + Illumina HiSeq 2000 platform[58] in cohorts of 48 and 203 HER2-positive breast cancer patients.